Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHA:600557)
12.64
-0.20 (-1.56%)
Apr 30, 2025, 3:00 PM CST
SHA:600557 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 2,195 | 1,969 | 1,601 | 937.44 | 768.81 | Upgrade
|
Trading Asset Securities | 40 | 460 | 170 | 176 | 4.5 | Upgrade
|
Cash & Short-Term Investments | 2,235 | 2,429 | 1,771 | 1,113 | 773.31 | Upgrade
|
Cash Growth | -7.99% | 37.15% | 59.08% | 43.98% | 89.05% | Upgrade
|
Accounts Receivable | 700.54 | 1,096 | 1,471 | 1,350 | 1,616 | Upgrade
|
Other Receivables | 6.33 | 5.32 | 9.67 | 11.75 | 9.82 | Upgrade
|
Receivables | 706.87 | 1,101 | 1,480 | 1,362 | 1,626 | Upgrade
|
Inventory | 540.27 | 350.11 | 342.82 | 338.08 | 376.53 | Upgrade
|
Other Current Assets | 113.69 | 169.03 | 135.32 | 60.91 | 110.3 | Upgrade
|
Total Current Assets | 3,596 | 4,050 | 3,730 | 2,874 | 2,886 | Upgrade
|
Property, Plant & Equipment | 2,752 | 2,508 | 2,508 | 2,533 | 2,557 | Upgrade
|
Long-Term Investments | 15.34 | 15.32 | 45.61 | 60.64 | 73.63 | Upgrade
|
Goodwill | 58.99 | 58.99 | 58.99 | 58.99 | 58.99 | Upgrade
|
Other Intangible Assets | 171.46 | 197.38 | 231.15 | 282.73 | 340.79 | Upgrade
|
Long-Term Deferred Tax Assets | 45.31 | 46.22 | 15.96 | 16.77 | 17.68 | Upgrade
|
Long-Term Deferred Charges | 203.84 | 186.1 | 184.79 | 171.14 | 164.69 | Upgrade
|
Other Long-Term Assets | 64.4 | 55.6 | 21.63 | 20.72 | 20.14 | Upgrade
|
Total Assets | 6,907 | 7,117 | 6,796 | 6,018 | 6,119 | Upgrade
|
Accounts Payable | 226.87 | 228.42 | 373.36 | 359.75 | 281 | Upgrade
|
Accrued Expenses | 29.06 | 1,027 | 814.57 | 531.14 | 528.47 | Upgrade
|
Short-Term Debt | - | - | - | 234.5 | 488 | Upgrade
|
Current Income Taxes Payable | 34.99 | 2.42 | 2.1 | 2.05 | 5.33 | Upgrade
|
Current Unearned Revenue | 25.46 | 25.17 | 214.87 | 25.34 | 26.5 | Upgrade
|
Other Current Liabilities | 1,728 | 325.54 | 376.2 | 300.08 | 366.75 | Upgrade
|
Total Current Liabilities | 2,044 | 1,609 | 1,781 | 1,453 | 1,696 | Upgrade
|
Long-Term Debt | - | 1.93 | 1.93 | 1.93 | 1.93 | Upgrade
|
Long-Term Unearned Revenue | 155.27 | 126.16 | 78.78 | 90.52 | 93.81 | Upgrade
|
Other Long-Term Liabilities | 1.93 | - | - | - | - | Upgrade
|
Total Liabilities | 2,202 | 1,737 | 1,862 | 1,545 | 1,792 | Upgrade
|
Common Stock | 581.8 | 584.75 | 584.6 | 592.88 | 592.88 | Upgrade
|
Additional Paid-In Capital | - | 111.79 | 98.13 | 171.79 | 174.57 | Upgrade
|
Retained Earnings | 4,145 | 4,544 | 4,136 | 3,720 | 3,399 | Upgrade
|
Treasury Stock | -211.98 | -48.14 | -64.7 | -180 | - | Upgrade
|
Total Common Equity | 4,515 | 5,193 | 4,754 | 4,304 | 4,167 | Upgrade
|
Minority Interest | 190.51 | 187.76 | 179.8 | 168.35 | 160.13 | Upgrade
|
Shareholders' Equity | 4,705 | 5,381 | 4,934 | 4,473 | 4,327 | Upgrade
|
Total Liabilities & Equity | 6,907 | 7,117 | 6,796 | 6,018 | 6,119 | Upgrade
|
Total Debt | - | 1.93 | 1.93 | 236.43 | 489.93 | Upgrade
|
Net Cash (Debt) | 2,235 | 2,427 | 1,769 | 877.01 | 283.39 | Upgrade
|
Net Cash Growth | -7.92% | 37.19% | 101.75% | 209.48% | - | Upgrade
|
Net Cash Per Share | 3.88 | 4.21 | 3.05 | 1.53 | 0.47 | Upgrade
|
Filing Date Shares Outstanding | 576.95 | 583.9 | 594.68 | 576.43 | 592.88 | Upgrade
|
Total Common Shares Outstanding | 576.95 | 583.9 | 594.68 | 576.43 | 592.88 | Upgrade
|
Working Capital | 1,551 | 2,441 | 1,949 | 1,421 | 1,190 | Upgrade
|
Book Value Per Share | 7.82 | 8.89 | 7.99 | 7.47 | 7.03 | Upgrade
|
Tangible Book Value | 4,284 | 4,936 | 4,464 | 3,963 | 3,767 | Upgrade
|
Tangible Book Value Per Share | 7.43 | 8.45 | 7.51 | 6.87 | 6.35 | Upgrade
|
Buildings | - | 2,402 | 2,460 | 2,398 | 2,385 | Upgrade
|
Machinery | - | 1,248 | 1,233 | 1,191 | 1,162 | Upgrade
|
Construction In Progress | - | 227.25 | 98.54 | 82.9 | 14.48 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.